Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Eli Lilly (NYSE:LLY) recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

With a market cap of $736.1 billion, Eli Lilly and Company (LLY) is a leading American pharmaceutical firm headquartered in ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs now tops 50%. Notably, Lilly's market share is increasing while Novo ...

Eli Lilly has broken ground on a massive new research facility in Lebanon that will support hundreds of jobs and focus on ...

U.S. equities advanced at midday as President Donald Trump announced a new trade deal with the United Kingdom. The Dow Jones ...

The new research and development site will combine research, process development and clinical trial manufacturing ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an ...